Pathology, Cancer research, Prostate cancer, Internal medicine and Prostate are his primary areas of study. Pathology is closely attributed to Adenocarcinoma in his study. His Prostate cancer research is under the purview of Cancer.
His research in Internal medicine intersects with topics in Gastroenterology, Endocrinology and Oncology. The Prostatectomy research Lukas Bubendorf does as part of his general Prostate study is frequently linked to other disciplines of science, such as XIAP, therefore creating a link between diverse domains of science. His Tissue microarray study integrates concerns from other disciplines, such as In situ hybridization, Complementary DNA, Microarray, DNA microarray and Fluorescence in situ hybridization.
Lukas Bubendorf mainly focuses on Pathology, Internal medicine, Oncology, Prostate cancer and Cancer research. His research integrates issues of Fluorescence in situ hybridization and Adenocarcinoma in his study of Pathology. His Internal medicine research includes elements of Gastroenterology and Endocrinology.
The study incorporates disciplines such as Stage, Disease, Chemotherapy and Predictive marker in addition to Oncology. His Prostate cancer study combines topics from a wide range of disciplines, such as Prostate and Tissue microarray. His Cancer research study incorporates themes from Carcinogenesis, Tumor suppressor gene, Cancer cell, Metastasis and Tumor progression.
His primary areas of study are Internal medicine, Lung cancer, Oncology, Pathology and Cancer research. In the field of Internal medicine, his study on Immunohistochemistry, Biomarker, Clinical trial and Pembrolizumab overlaps with subjects such as In patient. His research on Immunohistochemistry focuses in particular on Tissue microarray.
His biological study spans a wide range of topics, including Liquid biopsy, PD-L1, Prostate cancer and Predictive biomarker. The Pathology study combines topics in areas such as Molecular pathology and Lung. His work deals with themes such as Cancer, Adenocarcinoma, Gene, Somatic evolution in cancer and PTEN, which intersect with Cancer research.
His primary scientific interests are in Internal medicine, Lung cancer, Oncology, Immunohistochemistry and Pathology. His Malignancy and Who classification study in the realm of Internal medicine interacts with subjects such as NUT midline carcinoma and Appropriate use. Lukas Bubendorf combines subjects such as Mutation, Predictive biomarker, Clinical trial and Immunotherapy with his study of Lung cancer.
In general Immunohistochemistry, his work in Tissue microarray is often linked to Best practice linking many areas of study. His work on Pathology is being expanded to include thematically relevant topics such as Androgen receptor. His work in Liquid biopsy addresses subjects such as Progressive disease, which are connected to disciplines such as Prostate cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tissue microarrays for high-throughput molecular profiling of tumor specimens
J Kononen;L Bubendorf;A Kallioniemi;M Bärlund.
Nature Medicine (1998)
Gene-Expression Profiles in Hereditary Breast Cancer
I Hedenfalk;D Duggan;Y Chen;M Radmacher.
The New England Journal of Medicine (2001)
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Lukas Bubendorf;Alain Schöpfer;Urs Wagner;Guido Sauter.
Human Pathology (2000)
Survey of Gene Amplifications during Prostate Cancer Progression by High-Throughput Fluorescence in Situ Hybridization on Tissue Microarrays
Lukas Bubendorf;Juha Kononen;Pasi Koivisto;Peter Schraml.
Cancer Research (1999)
Tissue Microarrays for Gene Amplification Surveys in Many Different Tumor Types
Peter Schraml;Juha Kononen;Lukas Bubendorf;Holger Moch.
Clinical Cancer Research (1999)
High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.
Holger Moch;Peter Schraml;Lukas Bubendorf;Martina Mirlacher.
American Journal of Pathology (1999)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Ming Sound Tsao;Keith M. Kerr;Mark Kockx;Mary Beth Beasley.
Journal of Thoracic Oncology (2018)
Loss of NKX3.1 Expression in Human Prostate Cancers Correlates with Tumor Progression1,2
Cai Bowen;Lukas Bubendorf;H. James Voeller;Rebecca Slack.
Cancer Research (2000)
Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies.
Lukas Bubendorf;Antonio Nocito;Holger Moch;Guido Sauter.
The Journal of Pathology (2001)
Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays
Lukas Bubendorf;Meelis Kolmer;Meelis Kolmer;Juha Kononen;Pasi Koivisto.
Journal of the National Cancer Institute (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: